Tekmira Delays Clinical Trial for Cholesterol Drug as it Evaluates Alternative LNP Formulations

The company noted that since it develops LNP formulations individually for each of its drug candidates, the delay in TKM-apoB will have "no impact" on any of its other drug programs or those of its collaboration partners, who include Roche and Pfizer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.